ECSP014082A - Combinacion de secretagogos de hormona del crecimiento y antidepresivos - Google Patents

Combinacion de secretagogos de hormona del crecimiento y antidepresivos

Info

Publication number
ECSP014082A
ECSP014082A EC2001004082A ECSP014082A ECSP014082A EC SP014082 A ECSP014082 A EC SP014082A EC 2001004082 A EC2001004082 A EC 2001004082A EC SP014082 A ECSP014082 A EC SP014082A EC SP014082 A ECSP014082 A EC SP014082A
Authority
EC
Ecuador
Prior art keywords
growth
secretagogos
antidepressants
hormone
combination
Prior art date
Application number
EC2001004082A
Other languages
English (en)
Inventor
Frank Robert Busch
Willard Mckowan Welch
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP014082A publication Critical patent/ECSP014082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención esta dirigida a combinaciones que comprenden un secretagogo de hormona del crecimiento, un pro fármaco de este o una sal farmacéuticamente aceptable del citado secretagogo de la hormona de crecimiento o del citado profármaco y un antidepresivo, un profármaco de este o una sal farmacéuticamente aceptable del citado antidepresivo o del citado profármaco y a composiciones farmacéuticas y estuches que comprenden dichas combinaciones.
EC2001004082A 2000-05-25 2001-05-24 Combinacion de secretagogos de hormona del crecimiento y antidepresivos ECSP014082A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20701700P 2000-05-25 2000-05-25

Publications (1)

Publication Number Publication Date
ECSP014082A true ECSP014082A (es) 2002-04-23

Family

ID=22768871

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004082A ECSP014082A (es) 2000-05-25 2001-05-24 Combinacion de secretagogos de hormona del crecimiento y antidepresivos

Country Status (17)

Country Link
US (1) US20020002137A1 (es)
EP (1) EP1284753A2 (es)
JP (1) JP2003534294A (es)
AR (1) AR028620A1 (es)
AU (1) AU2001255013A1 (es)
BR (1) BR0111002A (es)
CA (1) CA2408036A1 (es)
DO (1) DOP2001000154A (es)
EC (1) ECSP014082A (es)
GT (1) GT200100089A (es)
MX (1) MXPA02011554A (es)
PA (1) PA8517701A1 (es)
PE (1) PE20011262A1 (es)
SV (1) SV2001000465A (es)
TN (1) TNSN01076A1 (es)
UY (1) UY26731A1 (es)
WO (1) WO2001089570A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021555A1 (ja) * 2003-08-29 2005-03-10 Takeda Pharmaceutical Company Limited 二環性ピペラジン化合物およびその用途
JP2005306839A (ja) * 2003-08-29 2005-11-04 Takeda Chem Ind Ltd 二環性ピペラジン化合物およびその用途
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
WO2022087011A1 (en) 2020-10-21 2022-04-28 Aligos Therapeutics, Inc. Bicyclic compounds
WO2022266193A1 (en) 2021-06-18 2022-12-22 Aligos Therapeutics, Inc. Bicyclic compounds
CA3255324A1 (en) 2022-04-20 2023-10-26 Aligos Therapeutics, Inc. BICYCLE COMPOUNDS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6251902B1 (en) * 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues

Also Published As

Publication number Publication date
SV2001000465A (es) 2001-07-03
BR0111002A (pt) 2003-04-15
CA2408036A1 (en) 2001-11-29
US20020002137A1 (en) 2002-01-03
AU2001255013A1 (en) 2001-12-03
TNSN01076A1 (fr) 2005-11-10
AR028620A1 (es) 2003-05-14
EP1284753A2 (en) 2003-02-26
UY26731A1 (es) 2001-12-28
PE20011262A1 (es) 2001-12-11
WO2001089570A2 (en) 2001-11-29
PA8517701A1 (es) 2002-12-30
JP2003534294A (ja) 2003-11-18
MXPA02011554A (es) 2003-04-25
WO2001089570A3 (en) 2002-06-20
GT200100089A (es) 2002-01-11
DOP2001000154A (es) 2002-05-15

Similar Documents

Publication Publication Date Title
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
BR0015188A (pt) Composições farmacêuticas
ATE513541T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin
ATE300306T1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
UY28001A1 (es) Derivados de azol-pirimidina condensados
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
SE0101932D0 (sv) Pharmaceutical combinations
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
ITRM20020562A1 (it) Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
GT200100089A (es) Combinacion de secretagogos de hormona de crecimiento y antidepresivos.
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
ES2175827T3 (es) Formulaciones transmucosas de levosimendano.
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
AR014082A1 (es) Concentrado oral de sertralina
PA8496801A1 (es) Complejo farmaceutico
ITRM20010293A1 (it) Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
HRP20070081T3 (hr) Nazalni farmaceutski pripravak piribedila
BR0013921A (pt) Composições farmacêuticas para tratamento de psorìase